tetano
Editor, Senior Moderator
J Microbiol. 2013 Oct;51(5):682-8. doi: 10.1007/s12275-013-3411-3. Epub 2013 Oct 31.
Adjuvant efficacy of mOMV against avian influenza virus infection in mice.
Lee BJ, Lee SH, Song MS, Pascua PN, Kwon HI, Park SJ, Kim EH, Decano A, Kim SM, Lim GJ, Kim DJ, Chang KT, Kim SH, Choi YK.
Source
College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, 361-763, Republic of Korea.
Abstract
Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 10(3.5) EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.
PMID:
24173647
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24173647
Adjuvant efficacy of mOMV against avian influenza virus infection in mice.
Lee BJ, Lee SH, Song MS, Pascua PN, Kwon HI, Park SJ, Kim EH, Decano A, Kim SM, Lim GJ, Kim DJ, Chang KT, Kim SH, Choi YK.
Source
College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, 361-763, Republic of Korea.
Abstract
Highly pathogenic avian influenza H5N1 viruses are found chiefly in birds and have caused severe disease and death in infected humans. Development of influenza vaccines capable of inducing heterosubtypic immunity against a broad range of influenza viruses is the best option for the preparedness, since vaccination remains the principal method in controlling influenza viral infections. Here, a mOMV-adjuvanted recombinant H5N2 (rH5N2) whole virus antigen vaccine with A/Environment/Korea/W149/06(H5N1)-derived H5 HA and A/Chicken/Korea/ma116/04(H9N2)-derived N2 NA in the backbone of A/Puerto Rico/8/34(H1N1) was prepared and generated by reverse genetics. Groups of mice were vaccinated by a prime-boost regime with the rH5N2 vaccine (1.75 μg of HA with/without 10 μg mOMV or aluminum hydroxide adjuvant for comparison). At two weeks post-immunizations, vaccinated mice were challenged with lethal doses of 10(3.5) EID50/ml of H5N1 or H9N2 avian influenza viruses, and were monitored for 15 days. Both mOMV- and alum-adjuvant vaccine groups had high survival rates after H5N1 infection and low levels of body weight changes compared to control groups. Interestingly, the mOMV-adjuvanted group induced better cross-reactive antibody responses serologically and promoted cross-protectivity against H5N1 and H9N2 virus challenges. Our results suggest that mOMV could be used as a vaccine adjuvant in the development of effective vaccines used to control influenza A virus transmission.
PMID:
24173647
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/24173647